Shares Outstanding Shares Outstanding n/a Close	228.36M
Shares Change (YoY) Shares Change (YoY) n/a Close	20.94%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	3.6%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	56.73%
Shares Floating Shares Floating n/a Close	227.36M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	2,978
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.2%

Short Selling Information

The latest short interest is 29.41M, so 12.88% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	29.41M
Short % of Shares Out Short % of Shares Out n/a Close	12.88%
Short % of Float Short % of Float n/a Close	22.98%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	22.15

Valuation Ratios

The PE ratio is -5.41 and the forward PE ratio is -16.34. Lineage Cell Therapeutics's PEG ratio is 0.22.

PE Ratio PE Ratio n/a Close	-5.41
Forward PE Forward PE n/a Close	-16.34
PS Ratio PS Ratio n/a Close	10.59
Forward PS Forward PS n/a Close	4.6
PB Ratio PB Ratio n/a Close	1.28
P/FCF Ratio P/FCF Ratio n/a Close	-4.25
PEG Ratio PEG Ratio n/a Close	0.22

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Lineage Cell Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 3.65, with a Debt / Equity ratio of 0.03.

Current Ratio Current Ratio n/a Close	3.65
Quick Ratio Quick Ratio n/a Close	3.65
Debt / Equity Debt / Equity n/a Close	0.03
Debt / EBITDA Debt / EBITDA n/a Close	-0.12
Debt / FCF Debt / FCF n/a Close	-0.11
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$135,700
Profits Per Employee Profits Per Employee n/a Close	$-265,842.86
Employee Count Employee Count n/a Close	70
Asset Turnover Asset Turnover n/a Close	0.08
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	27K
Effective Tax Rate Effective Tax Rate n/a Close	-0.15%

Stock Price Statistics

The stock price has increased by -6.09% in the last 52 weeks. The beta is 1.52, so Lineage Cell Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	1.52
52-Week Price Change 52-Week Price Change n/a Close	-6.09%
50-Day Moving Average 50-Day Moving Average n/a Close	0.54
200-Day Moving Average 200-Day Moving Average n/a Close	0.65
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	76.09
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,471,665

Income Statement

In the last 12 months, Lineage Cell Therapeutics had revenue of 9.5M and earned -18.61M in profits. Earnings per share was -0.09.

Revenue Revenue n/a Close	9.5M
Gross Profit Gross Profit n/a Close	9.16M
Operating Income Operating Income n/a Close	-21.48M
Net Income Net Income n/a Close	-18.61M
EBITDA EBITDA n/a Close	-20.87M
EBIT EBIT n/a Close	-21.48M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-0.09

Full Income Statement

Balance Sheet

The company has 45.79M in cash and 2.51M in debt, giving a net cash position of 43.27M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	45.79M
Total Debt Total Debt n/a Close	2.51M
Net Cash Net Cash n/a Close	43.27M
Retained Earnings Retained Earnings n/a Close	-403.46M
Total Assets Total Assets n/a Close	111.75M
Working Capital Working Capital n/a Close	36.9M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.09M and capital expenditures -565K, giving a free cash flow of -23.66M.

Operating Cash Flow Operating Cash Flow n/a Close	-23.09M
Capital Expenditures Capital Expenditures n/a Close	-565K
Free Cash Flow Free Cash Flow n/a Close	-23.66M
FCF Per Share FCF Per Share n/a Close	-0.12

Full Cash Flow Statement

Margins

Gross margin is 96.48%, with operating and profit margins of -226.11% and -195.9%.

Gross Margin Gross Margin n/a Close	96.48%
Operating Margin Operating Margin n/a Close	-226.11%
Pretax Margin Pretax Margin n/a Close	-195.62%
Profit Margin Profit Margin n/a Close	-195.9%
EBITDA Margin EBITDA Margin n/a Close	-219.7%
EBIT Margin EBIT Margin n/a Close	-226.11%
FCF Margin FCF Margin n/a Close	-249.05%

Dividends & Yields

LCTX does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for LCTX is $3, which is 252.9% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$3
Price Target Difference Price Target Difference n/a Close	252.9%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Oct 31, 1997. It was a forward split with a ratio of 3:1.

Last Split Date Last Split Date n/a Close	Oct 31, 1997
Split Type Split Type n/a Close	forward
Split Ratio Split Ratio n/a Close	3:1

Scores

Altman Z-Score Altman Z-Score n/a Close	-2.62
Piotroski F-Score Piotroski F-Score n/a Close	3